5-Amino-1MQ
Studied for: metabolic enzyme research
5-Amino-1MQ is a small molecule studied as an inhibitor of nicotinamide N-methyltransferase, an enzyme associated with fat-cell metabolism and cellular NAD+ availability.
Last reviewed September 26, 2026
How it is thought to work
Research investigates 5-Amino-1MQ for NNMT inhibition, which is studied for downstream effects on adipocyte energy expenditure and the salvage pathway that regenerates NAD+.
- NNMT InhibitionStudied for inhibiting an enzyme highly expressed in adipose tissue and linked to metabolic rate.
- NAD+ SalvageExplored for knock-on effects on the pathway that recycles NAD+ within the cell.
- Route studied
- Subcutaneous
- Research status
- Preclinical
Published research on NNMT inhibition, including work relevant to 5-Amino-1MQ, consists of animal and cell studies, and no human clinical trials are identified in the cited literature.
Research
What the research covers
What research examines
- NNMT inhibition in adipose tissue
- Obesity-related metabolic dysfunction in preclinical models
- Adipocyte energy expenditure
- NAD+ salvage pathway effects
- Limb function in experimental peripheral artery disease
Reported effects in studies
- Human safety data are limited
- Adverse events are not summarized in the cited preclinical studies
- Supplied for laboratory research use only
Studied range
What research protocols have used
Research protocols have used 2.5–5 mg per administration, once daily (morning), in 8-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorRelated compounds
Researched alongside
- GLP-3RGLP-3R is studied as a triple agonist at the GLP-1, GIP, and glucagon receptors. Research examines whether engaging all three affects metabolic regulation differently to dual or single agonists.Read profile$119
- TirzepatideTirzepatide is studied as a dual agonist at the GIP and GLP-1 receptors. Research examines whether combining the two incretin pathways differs from GLP-1 agonism alone.Read profile$139
- AOD-9604AOD 9604 is a synthetic peptide derived from the C-terminal fragment of human growth hormone, isolated for research into fat metabolism without the broader activity of the full hormone.Read profile$89
- TesamorelinTesamorelin is a stabilized growth-hormone-releasing hormone analog. Research examines its role in endogenous GHRH signaling and its association with visceral adipose tissue.Read profile$99
Studies
Cited research
- Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction.
Diabetes, obesity & metabolism · 2024 · PMID 39161060
- Nicotinamide N-methyltransferase inhibition improves limb function in experimental peripheral artery disease.
Physiological reports · 2025 · PMID 41108586
FAQ
Questions about 5-Amino-1MQ
5-Amino-1MQ is a small molecule studied as an inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme associated with fat-cell metabolism and cellular NAD+ availability. It is investigated in metabolic enzyme research, mainly in preclinical settings. It is not a peptide in the strict sense, but is commonly grouped with research compounds of interest in metabolic and performance-related studies. CoreX supplies it for laboratory research use only.
Research investigates 5-Amino-1MQ for its inhibition of NNMT, an enzyme highly expressed in adipose tissue and linked to metabolic rate. Blocking NNMT is studied for downstream effects on adipocyte energy expenditure. Researchers have also explored knock-on effects on the NAD+ salvage pathway, which recycles NAD+ within the cell. These mechanisms are proposed from laboratory and animal work, and their relevance in humans has not been established.
Preclinical studies have examined NNMT inhibition in models of obesity-related metabolic dysfunction, reporting effects on metabolic measures in animals. Other animal work has studied NNMT inhibition in experimental peripheral artery disease, with reported improvements in limb function. Broader NNMT research has also looked at the enzyme's role in fatty liver development and in tumour biology. These findings are early and come from animal and cell models rather than human trials.
Human safety data for 5-Amino-1MQ are limited, as research to date has been largely preclinical. Adverse events are not summarized in the cited animal studies, and no controlled human trials establishing a safety profile have been identified. Because of this, conclusions about tolerability, interactions or long-term effects cannot be drawn. The compound is supplied strictly for laboratory research use and is not approved for any medical indication.
Research protocols have used 2.5 to 5 mg per administration, once daily in the morning, via the subcutaneous route, run in 8-week blocks followed by 4 weeks off. These figures describe amounts reported in research protocols and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference. Given the preclinical status of this compound, such protocols have not been validated in controlled human studies.
Ask about 5-Amino-1MQ
Plain answers from our library: the science, the studied ranges and our products. It can be wrong, and it does not give medical advice.
AI answers can be wrong. Research use only.